Brief: U.S. FDA Grants Spectral Medical Breakthrough Device Designation For Toraymyxin
11/07/2022 13:26
July 11 (Reuters) - Spectral Medical Inc EDT.TO :
* US FDA GRANTS SPECTRAL MEDICAL BREAKTHROUGH DEVICE
DESIGNATION
FOR TORAYMYXIN™ (“PMX”) FOR THE TREATMENT OF ENDOTOXEMIC SEPTIC
SHOCK
Source text for Eikon: ID:nGNX82Pjsq
Further company coverage: EDT.TO
((reuters.briefs@thomsonreuters.com;))
Recent news on Spectral Medical
See all newsBrief: Spectral Medical Provides Update Following In-Person FDA 100-Day Meeting For PMX PMA
Canada's Spectral Medical Q2 revenue falls on lower reagent sales
Brief: Spectral Medical And Vantive Announce Topline 12 Month Follow-Up Results From Spectral’S Tigris Trial
Canada's Spectral Medical Q1 revenue rises 56%, net loss narrows
Spectral Medical Q3 revenue up 34%